RxDoctor Payments Data

Amy Lewis

Nurse Practitioner · Mansfield, TXNPI 1164793246

Payments from drug & device makers

$11,891in general payments, 2019–2025

Across 752 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$721
  • SK Life Science, Inc.$708
  • Pfizer$693
  • Amgen$636
  • Teva Pharmaceuticals USA, Inc.$627
  • plus $6K from 45 others

What the payments were for

  • Food & beverage$11,77899%
  • Education$1131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,891 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$54,292
Medicare patients
253
Services billed
522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant55$74,997
Nurtec OdtRimegepant Sulfate41$73,801
CopaxoneGlatiramer Acetate12$71,380
QuliptaAtogepant33$44,808
Emgality PenGalcanezumab-Gnlm45$40,609
VimpatLacosamide17$34,706
Topiramate ErTopiramate21$34,224
NamzaricMemantine Hcl/Donepezil Hcl27$26,988
RexultiBrexpiprazole14$26,977
Aimovig AutoinjectorErenumab-Aooe24$23,006
XcopriCenobamate15$18,555
RytaryCarbidopa/Levodopa27$17,586
BelsomraSuvorexant32$15,998
Lamictal OdtLamotrigine13$15,163
Trokendi XrTopiramate11$14,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Namzaric$2,487$146,793115 claims
PfizerNurtec Odt$693$73,80141 claims
Teva Pharmaceuticals USA, Inc.Copaxone$627$71,38012 claims
UCB, Inc.Vimpat$721$34,70617 claims
Otsuka America Pharmaceutical, Inc.Rexulti$256$26,97714 claims
SK Life Science, Inc.Xcopri$708$18,55515 claims
Amneal Pharmaceuticals LLCRytary$363$17,58627 claims
MerckBelsomra$31$15,99832 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$123$14,83811 claims
Neurocrine Biosciences, Inc.Ongentys$380$12,15418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Mansfield

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →